CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in Mirxes Pte Ltd., a Singapore-based company at the forefront of miRNA technology. This funding is poised to propel Mirxes’ swift growth and its global outreach in the realm of cancer early detection and precision medicine.
Mirxes’ Leadership in miRNA Testing
Mirxes stands out as a pioneer in crafting and launching precise, non-invasive, and cost-effective blood-based miRNA tests. Its flagship product, GASTROClear, marks a milestone as the world’s first and only In Vitro Diagnostics (IVD) product for gastric cancer screening. Since gaining regulatory approval in Singapore in 2019, GASTROClear has redefined standards with an 87.5% sensitivity for detecting stage 1 cancers and a 75% sensitivity for lesions under 1 cm. A recent prospective clinical trial in China, involving 9,472 participants, further underscored GASTROClear’s safety and efficacy as a groundbreaking screening tool for gastric cancer.
Innovation and Market Expansion
Backed by an industry-leading portfolio of over 90 patents and applications, Mirxes is relentlessly expanding its miRNA technology platform. The company is currently in the process of developing diagnostic solutions for lung, liver, and colorectal cancer. Mirxes is particularly focused on scaling up its operations in the high-growth Asia Pacific region, encompassing Southeast Asia, China, and Japan, to bring its innovative cancer detection solutions to a broader patient population.-Fineline Info & Tech
